Hickman G, Duval A, Picard C, Petit A
Service de dermatologie, hôpital Saint-Louis, Assistance publique-Hôpitaux de Paris, 1, avenue Claude-Vellefaux, 75010 Paris, France.
Ann Dermatol Venereol. 2010 Jan;137(1):36-9. doi: 10.1016/j.annder.2009.10.179. Epub 2009 Nov 11.
Voriconazole is a systemic antifungal drug that can induce phototoxic reactions suggestive of porphyria cutanea tarda (PCT); however, porphyrin levels in urine, blood and stool remain within the normal range. Superficial cheilitis is frequently associated with this clinical picture; it is believed to be related to drug-induced impairment of endogenous retinoid metabolism. We report a case of true PCT associated with cheilitis, both occurring soon after the introduction of voriconazole and partially disappearing after withdrawal of this drug.
A 65-year-old man with a past history of excessive alcohol consumption presented with typical features of PCT associated with a mild superficial desquamating cheilitis. Both symptoms had appeared 12 days after initiation of oral voriconazole for a cavitary aspergillosis. Laboratory tests confirmed a sporadic case of PCT. Withdrawal of voriconazole (replaced by itraconazole) resulted in complete disappearance of the cheilitis but incomplete remission of the PCT. Ultimately, the patient was successfully treated by venous puncture.
This patient had both voriconazole-induced superficial cheilitis and a true PCT which seemed related to the same drug. The mechanism by which voriconazole may have revealed PCT remains elusive and could possibly have involved decreased uroporphyrinogen decarboxylase activity in the liver or potentiation of the phototoxic effects of porphyrins by the cutaneous toxicity of voriconazole.
On presentation of a clinical picture of PCT-like photosensitivity in a patient on voriconazole, laboratory investigations should be performed routinely to rule out true PCT, even in cases of associated cheilitis.
伏立康唑是一种全身性抗真菌药物,可诱发提示迟发性皮肤卟啉症(PCT)的光毒性反应;然而,尿液、血液和粪便中的卟啉水平仍在正常范围内。浅表性唇炎常与这种临床表现相关;据信它与药物引起的内源性类维生素A代谢受损有关。我们报告一例与唇炎相关的真性PCT病例,两者均在开始使用伏立康唑后不久出现,并在停用该药物后部分消失。
一名有过量饮酒史的65岁男性,出现了PCT的典型特征,并伴有轻度浅表脱屑性唇炎。这两种症状在口服伏立康唑治疗空洞型曲霉病12天后出现。实验室检查证实为散发性PCT病例。停用伏立康唑(改用伊曲康唑)后,唇炎完全消失,但PCT未完全缓解。最终,患者通过静脉穿刺成功治愈。
该患者既有伏立康唑引起的浅表性唇炎,又有真性PCT,这两者似乎与同一种药物有关。伏立康唑可能揭示PCT的机制仍不清楚,可能涉及肝脏中尿卟啉原脱羧酶活性降低,或伏立康唑的皮肤毒性增强了卟啉的光毒性作用。
对于服用伏立康唑的患者出现类似PCT的光敏临床表现时,即使伴有唇炎,也应常规进行实验室检查以排除真性PCT。